BioStock: BiBBInstruments resumes key clinical trials

Cancer diagnostics company BiBBInstruments released its 2020 annual report last week where the company outlines its main achievements from last year, including the launch of clinical evaluation of the world’s first CE-marked electric endoscopic biopsy instrument. Due to production problems, in April 2021, BiBBInstruments had to pause the recruitment of patients in its two ongoing clinical studies. However, in mid-May, after intensive work, the company was able to announce that studies could be resumed after a complete change of supplier.

Read the article at biostock.se:

https://www.biostock.se/en/bibbinstruments-resumes-key-clinical-trials/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se